Zuellig Pharma, a prominent healthcare company in Asia, has started a new high-tech Clinical Trial Support (CTS) Innovation Center in South Korea. This new initiative reflects Zuellig Pharma’s consistent commitment towards enhancing the healthcare field as well as its role as a trusted partner in the region.
Located near the Gyeongbu Expressway in Gyeonggi-do province, the 3,800-square-meter center is designed to improve clinical trial logistics using automation, digital technology, and strict safety standards. It aims to make operations faster, more efficient, and reliable across different areas of healthcare.
The facility has advanced features, including a fully automated system for faster as well as delivery of clinical supplies with utmost precision. It is also designed to operate smoothly and securely, with strong measures to protect sensitive clinical data.
The center can manage thousands of different clinical trial products, such as those that are to be stored at regulatory temperatures like cold, frozen, or even cryogenic degrees. This aids in ensuring that sensitive products are kept with precision throughout the whole operation.
The facility has special areas for repackaging products in guided environments, ensuring they meet strict clinical standards. It also includes a tracking system to monitor the whole process, ensuring the highest quality as well as compliance with regulations at every step.
Over the past year, the center has catered to over 3,000 studies, working with more than 100 clients. It has handled about 13,000 shipments every year, including chemicals, medical devices, and treatments like gene therapies.
Executive Statement
According to John Graham, CEO of Zuellig Pharma, as part of an integrated healthcare solutions company, this milestone marks a significant step forward for Zuellig Pharma in remaining agile and responsive to the evolving clinical trial landscape. It also showcases Zuellig Pharma's continued commitment to advancing healthcare through innovation along with sustainable infrastructure, creating greater access to treatments and delivering meaningful outcomes for partners and communities they serve.
